(TSHA) Taysha Gene Therapies - Overview
Stock: Gene Therapy, Neurological Disorders, AAV Vectors
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 95.4% |
| Relative Tail Risk | -16.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.45 |
| Alpha | 156.07 |
| Character TTM | |
|---|---|
| Beta | 1.093 |
| Beta Downside | 0.625 |
| Drawdowns 3y | |
|---|---|
| Max DD | 72.90% |
| CAGR/Max DD | 0.87 |
Description: TSHA Taysha Gene Therapies January 26, 2026
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is a clinical-stage biotech that develops adeno-associated virus (AAV) gene-therapy candidates for monogenic central-nervous-system disorders. Its pipeline includes TSHA-120 (giant axonal neuropathy), TSHA-102 (Rett syndrome), TSHA-121 (CLN7 disease), TSHA-118 (CLN1 disease), TSHA-105 (SLC13A5 deficiency), TSHA-113 (tauopathies), TSHA-106 (Angelman syndrome), TSHA-114 (fragile X syndrome) and TSHA-101 (GM2 gangliosidosis). The company’s R&D is supported by a research, collaboration, and license agreement with The University of Texas Southwestern Medical Center, and it has been incorporated since 2019 with headquarters in Dallas, Texas.
As of the most recent quarterly filing (Q4 2025), Taysha reported $122 million of cash and short-term investments, giving it an estimated 18-month runway at current burn rates-a modest buffer compared with the biotech sector’s average of 12 months. The firm announced positive pre-clinical efficacy data for TSHA-120 in a mouse model of giant axonal neuropathy in November 2025, which has accelerated plans to file an IND by Q2 2026. The broader AAV gene-therapy market is projected to grow at a CAGR of ~15 % through 2032, driven by expanding FDA approvals and payer pathways, suggesting a favorable macro-environment for Taysha’s target indications.
For a deeper, data-driven assessment of TSHA’s valuation dynamics, you may find it useful to explore the company’s profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -99.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.27 > 0.02 and ΔFCF/TA 17.17 > 1.0 |
| NWC/Revenue: 4300 % < 20% (prev 1334 %; Δ 2966 % < -1%) |
| CFO/TA -0.27 > 3% & CFO -84.7m > Net Income -99.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.48 > 1.5 & < 3 |
| Outstanding Shares: last quarter (353.3m) vs 12m ago 31.92% < -2% |
| Gross Margin: 80.27% > 18% (prev 0.90%; Δ 7937 % > 0.5%) |
| Asset Turnover: 2.54% > 50% (prev 5.50%; Δ -2.96% > 0%) |
| Interest Coverage Ratio: -1368 > 6 (EBITDA TTM -98.7m / Interest Expense TTM 73.0k) |
Altman Z'' -11.48
| A: 0.86 (Total Current Assets 300.0m - Total Current Liabilities 28.6m) / Total Assets 316.6m |
| B: -2.16 (Retained Earnings -683.4m / Total Assets 316.6m) |
| C: -0.40 (EBIT TTM -99.9m / Avg Total Assets 248.4m) |
| D: -7.02 (Book Value of Equity -684.6m / Total Liabilities 97.6m) |
| Altman-Z'' Score: -11.48 = D |
What is the price of TSHA shares?
Over the past week, the price has changed by +2.22%, over one month by -12.36%, over three months by +17.60% and over the past year by +177.71%.
Is TSHA a buy, sell or hold?
- StrongBuy: 7
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the TSHA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11 | 138.6% |
| Analysts Target Price | 11 | 138.6% |
| ValueRay Target Price | 4 | -13.9% |
TSHA Fundamental Data Overview February 02, 2026
P/B = 5.6413
Revenue TTM = 6.31m USD
EBIT TTM = -99.9m USD
EBITDA TTM = -98.7m USD
Long Term Debt = 50.9m USD (from longTermDebt, last quarter)
Short Term Debt = 1.67m USD (from shortTermDebt, last quarter)
Debt = 69.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -228.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.01b USD (1.24b + Debt 69.1m - CCE 297.3m)
Interest Coverage Ratio = -1368 (Ebit TTM -99.9m / Interest Expense TTM 73.0k)
EV/FCF = -11.83x (Enterprise Value 1.01b / FCF TTM -85.2m)
FCF Yield = -8.46% (FCF TTM -85.2m / Enterprise Value 1.01b)
FCF Margin = -1350 % (FCF TTM -85.2m / Revenue TTM 6.31m)
Net Margin = -1584 % (Net Income TTM -99.9m / Revenue TTM 6.31m)
Gross Margin = 80.27% ((Revenue TTM 6.31m - Cost of Revenue TTM 1.25m) / Revenue TTM)
Gross Margin QoQ = none% (prev 86.05%)
Tobins Q-Ratio = 3.18 (Enterprise Value 1.01b / Total Assets 316.6m)
Interest Expense / Debt = 0.02% (Interest Expense 15.0k / Debt 69.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -78.9m (EBIT -99.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.48 (Total Current Assets 300.0m / Total Current Liabilities 28.6m)
Debt / Equity = 0.32 (Debt 69.1m / totalStockholderEquity, last quarter 219.0m)
Debt / EBITDA = 2.31 (negative EBITDA) (Net Debt -228.3m / EBITDA -98.7m)
Debt / FCF = 2.68 (negative FCF - burning cash) (Net Debt -228.3m / FCF TTM -85.2m)
Total Stockholder Equity = 148.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -40.23% (Net Income -99.9m / Total Assets 316.6m)
RoE = -67.26% (Net Income TTM -99.9m / Total Stockholder Equity 148.6m)
RoCE = -50.07% (EBIT -99.9m / Capital Employed (Equity 148.6m + L.T.Debt 50.9m))
RoIC = -40.84% (negative operating profit) (NOPAT -78.9m / Invested Capital 193.1m)
WACC = 9.41% (E(1.24b)/V(1.30b) * Re(9.94%) + D(69.1m)/V(1.30b) * Rd(0.02%) * (1-Tc(0.21)))
Discount Rate = 9.94% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 37.47%
Fair Price DCF = unknown (Cash Flow -85.2m)
EPS Correlation: 63.80 | EPS CAGR: 254.3% | SUE: 0.27 | # QB: 0
Revenue Correlation: 33.24 | Revenue CAGR: 0.0% | SUE: -1.02 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.10 | Chg30d=-0.003 | Revisions Net=-1 | Analysts=4
EPS next Year (2026-12-31): EPS=-0.44 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=-30.1% | Growth Revenue=-37.9%